| abstract |
The present invention relates to fusion proteins having the Fc domain of human immunoglobulin G (IgG), in particular wherein the Fc domain of human immunoglobulin G (IgG) and the soluble extracellular structure of the vascular endothelial growth factor (VEGF) receptor domain-fused proteins (eg, aflibercept) in stable liquid formulations. In addition, the present invention relates to compositions for stabilizing proteins in which the Fc domain of IgG is fused to a soluble extracellular domain of a VEGF receptor, and for stabilizing a protein in which the Fc domain of IgG is fused to a soluble extracellular domain of a VEGF receptor Methods for protein stabilization of domain fusions. The present invention improves the therapeutic effect of various ophthalmic diseases caused by abnormal angiogenesis (such as retinal vein occlusion, diabetic macular edema, choroidal neovascularization and wet age-related macular degeneration, etc.) Stable liquid formulation of aflibercept's anti-VEGF-Fc fusion protein to pursue stabilization of biological activity. |